You are here: Home » PTI Stories » National » News
Business Standard

Zydus Hospira Oncology gets EIR for its Ahmedabad facility

Press Trust of India  |  New Delhi 

Drug firm today said Zydus Oncology, a JV between the company and Inc, has received Establishment Inspection Report (EIR) from the US regulator for its Ahemdabad

The from the Food and Drug Administration (USFDA) has concluded that the inspection is closed but has also said that the inspection classification of this facility is 'voluntary action indicated' (VAI).

According to the USFDA, VAI means that though objectionable conditions were found and documented, but the agency is not prepared to take or recommend regulatory action.

Zydus Hopsira Oncology is a 50:50 joint venture company between and Inc USA (now part of Pfizer Group), said.

The had completed the USFDA audit from April 5 to April 12, 2018, it added.

Shares of Cadila Healthcare, the listed entity of the group, were ended at Rs 366.30 per scrip in the afternoon trade on BSE, down 1.40 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, July 12 2018. 15:45 IST